Abdera Therapeutics’ Post

While we have witnessed digital capabilities navigating the pharma through evolving landscape, the question in the realm of CGT remains - how much closer are we to demonstrating value using the universal language of data? Join senior leader from Sumitomo Pharma America, Microvascular Therapeutics, Mustang Bio and Bayer next month, to explore their visions on key trends shaping the future of CGT clinical development: https://bit.ly/3OkH4Ly

While we have witnessed digital capabilities navigating the pharma through evolving landscape, the question in the realm of CGT remains - how much closer are we to demonstrating value using the universal language of data? Join senior leader from Sumitomo Pharma America, Microvascular Therapeutics, Mustang Bio and Bayer next month, to explore their visions on key trends shaping the future of CGT clinical development: https://bit.ly/3OkH4Ly

🚀 We have some exciting news to share! Clarity Pharmaceuticals has signed a Clinical Manufacturing Agreement with us, enhancing our joint commitment to innovative healthcare solutions. This new agreement builds upon our previous Master Services and Supply Agreements, focusing on the streamlined production of the 64Cu isotope and the 64Cu-SAR-bisPSMA product at a single facility. As part of the agreement, SpectronRx will ensure reliable, on-demand manufacturing and distribution of Clarity’s novel diagnostic, 64Cu-SAR-bisPSMA, across all 50 states. This will enable universal access to Clarity’s Phase III trials, including the ongoing CLARIFY trial and the upcoming pivotal trial for prostate cancer patients experiencing biochemical recurrence (BCR). This partnership enhances Clarity’s supply network with a robust, multifaceted approach unique to the radiopharmaceutical sector. Why is this significant? It guarantees a continuous and ample supply chain, providing widespread access to 64Cu-SAR-bisPSMA throughout the United States. 👉 You can read the full announcement in today's edition of BioSpace: https://lnkd.in/gzJWN5FT #NuclearMedicine #Radiopharmaceuticals #ClinicalTrials #SpectronRx #ClarityPharmaceuticals

These smart and beautiful ladies are ready to reply questions about #IBARadiopharmasolutions

Our proprietary tool, AssetNav, part of the InizioNavigator suite, has been developed to support clients in making smarter, faster decisions in the competitive pharmaceutical industry. In Executive Director, John L'Ecuyer's latest blog, learn how our people are using AssetNav to help inform critical clinical investment and BD&L decisions. Read the piece here: https://lnkd.in/eEmCt3Tg #PharmaInsights #DataAnalytics #BDL #Oncology #TherapeuticInnovation #AssetNav

Radiopharmaceuticals have proven to be effective agents since they can be successfully applied for both diagnostics and therapy. Radionuclide drug conjugates (RDCs) combine a radioactive compound, a tailored-targeting molecule for specific receptors enriched on diseased cells, and a linker for stable attachment. By attacking only cancerous cells, this approach enables more effective radiation delivery and significantly reduces side effects. WuXi AppTec has developed a comprehensive workflow for radiopharmaceutical discovery and development, from target selection and ligand ID to stability testing and in vivo efficacy/safety assessment. Curious to learn more? Watch the video ⬇️ https://lnkd.in/e_XeBg-C #DrugDiscovery #RDC #Radionuclide #Radiopharmaceutical

🚨A reminder to register for the upcoming webinar on how to accelerate the development and production of AAV-based therapeutics!  Learn from Regeneron’s Marília Barros and Refeyn’s Matthew Ranaghan about the best analytical strategies to analyze the ratios of empty/full/partial AAV ratios, capsid titers, sample purity and other key quality attributes essential for successful drug development. And of course, how to integrate #MassPhotometry in your workflows for fast, sample-efficient analysis. 🔬📊  Register here 👉 https://lnkd.in/dfMqa7dY

Tenosynovial Giant Cell Tumors Pipeline Insights and Analysis 2024: FDA Approvals, Therapies, MOA, ROA, and Developments | Deciphera Pharma, Elixiron Immunotherapeutics, Daiichi Sankyo, Abbisko Thera: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Tenosynovial Giant Cell Tumors pipeline constitutes 5+ key companies continuously working towards developing 5+ Tenosynovial Giant Cell Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

#Voximetry, #LetsTalk, #Theranostics, #RadioPharmaceuticalTherapy Worth the listen to these two experts in Nuclear Medicine regarding RPT!!

MEDIcept Minute: Upcoming FDA Webinar - "Regulatory Do’s and Don’ts: Tips from FDA” Exciting news for the industry! Join the FDA and NIH for their latest webinar regarding Regulatory Do’s and Don’ts on September 4, 2024, from 11 AM to 3 PM ET. This event is perfect for early-stage companies and academic spin-offs developing new anticancer therapeutics, devices, and diagnostics. Gain valuable insights into the resources and programs offered by FDA centers (CBER, CDER, CDRH) and learn when to engage with the FDA during preclinical development. Don't miss the Q&A sessions with FDA regulators. Learn more about how you can attend at the link below. https://lnkd.in/eyKhGgC5 For personalized regulatory support, contact MEDIcept Inc. at [email protected] for expert guidance in navigating FDA requirements. #FDA #RegulatoryAffairs #Webinar #MedicalDevices